Nature Search

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

DiNardo et al. perform a phase 1b/2 clinical trial of telaglenastat (CB-839) in combination with azacytidine in persons with advanced myelodysplastic syndromes and report on the treatment safety and efficacy, including a definition of clinical responders.

Courtney D. DiNardo
Divij Verma
Marina Konopleva
Research19 Sept 2024
Nature Cancer

Volume: 5, P: 1515-1533
Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development

Inflammasome activation may contribute to type 2 diabetes, but whether targeting inflammasome is beneficial is unclear. Here the authors show that repurposing nucleoside reverse transcriptase inhibitors for inhibiting inflammasome activation is associated with reduced diabetes development in people and improves insulin sensitivity in experimental settings.

Jayakrishna Ambati
Joseph Magagnoli
Bradley D. Gelfand
ResearchOpen Access23 Sept 2020
Nature Communications

Volume: 11, P: 1-12
Autophagy proteins regulate ERK phosphorylation

The spatial organisation of mitogen-activated protein kinase (MAPK) signalling by scaffold proteins is an important determinant of signalling specificity. Martinez-Lopez et al. show that pre-autophagosomal structures can also act as scaffolds, recruiting the MAPK ERK1/2 and regulating its phosphorylation.

Nuria Martinez-Lopez
Diana Athonvarangkul
Rajat Singh
ResearchOpen Access18 Nov 2013
Nature Communications

Volume: 4, P: 1-14
High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster

First responders to the World Trade Center disaster, who were exposed to particulate matter containing potential carcinogens, have a high burden of somatic mutations in blood cells, raising their risk for cancer and other diseases and highlighting the need for enhanced health screening of these individuals.

Sakshi Jasra
Orsi Giricz
Amit Verma
Research07 Mar 2022
Nature Medicine

Volume: 28, P: 468-471
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

Nora E. Rahmani
Nandini Ramachandra
Amit Verma
ResearchOpen Access21 Sept 2021
Blood Cancer Journal

Volume: 11, P: 1-8

Quick links

Search

Filter By:

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development

Autophagy proteins regulate ERK phosphorylation

High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

Search

Quick links